Abstract. Icariin, the major active component isolated from plants of the Epimedium family, has been reported to have potential protective effects on the cardiovascular system. However, it is not known whether icariin has a direct effect on angiotensin II (Ang II)-induced cardiomyocyte enlargement and apoptosis. In the present study, embryonic rat heart-derived H9c2 cells were stimulated by Ang II, with or without icariin administration. Icariin treatment was found to attenuate the Ang II-induced increase in mRNA expression levels of hypertrophic markers, including atrial natriuretic peptide and B-type natriuretic peptide, in a concentration-dependent manner. The cell surface area of Ang II-treated H9c2 cells also decreased with icariin administration. Furthermore, icariin repressed Ang II-induced cell apoptosis and protein expression levels of Bax and cleaved-caspase 3, while the expression of Bcl-2 was increased by icariin. In addition, 2',7'-dichlorofluorescein diacetate incubation revealed that icariin inhibited the production of intracellular reactive oxygen species (ROS), which were stimulated by Ang II. Phosphorylation of c-Jun N-terminal kinase (JNK) and p38 in Ang II-treated H9c2 cells was blocked by icariin. Therefore, the results of the present study indicated that icariin protected H9c2 cardiomyocytes from Ang II-induced hypertrophy and apoptosis by inhibiting the ROS-dependent JNK and p38 pathways.

Introduction

Cardiac hypertrophy occurs when the heart endures overload or injury. Although hypertrophy is an adaptive process that initially maintains cardiac output, sustained hypertrophy ultimately leads to heart failure, which is the leading cause of morbidity and mortality worldwide (1,2). Various stimuli, including mechanical stress and neurohumoral factors, such as angiotensin II (Ang II), endothelin-1, catecholamine and growth factors, are involved in the progression of cardiac hypertrophy (3). These stimuli activate membrane receptors and intracellular signaling pathways to mediate the transcription of hypertrophy-related genes (4). Enlargement and apoptotic loss of cardiomyocytes are the key pathological changes in cardiac hypertrophy (5). To prevent cardiomyocytes from enlargement and cell death, blocking the transition between adaptive hypertrophy and heart failure is necessary. However, the existing treatments that modify hemodynamics and inhibit active neurohumoral factors are not capable of successfully restoring the injured cardiomyocytes. Disrupting the intracellular signaling pathways that mediate cardiac hypertrophy has been increasingly studied and novel targets have been identified that may be used to explore therapeutic strategies for cardiac hypertrophy and heart failure.

Icariin (C33H40O15; molecular weight, 676.66), a prenylated flavonol glycoside, is the major active component isolated from plants of the Epimedium family (6). Multiple pharmacological properties of icariin have been revealed, including immunoregulation, antioxidative stress, antiapoptosis and stimulation of angiogenesis (6-9). Song et al (8) identified that icariin attenuated cardiac remodeling in rats with congestive heart failure by inhibiting matrix metalloproteinase (MMP) activity and protecting cardiomyocytes from apoptosis. This result demonstrates the cardiac protective role of icariin. However, it is not known whether icariin has a direct effect on cardiomyocytes and the mechanism underlying its cardiac protective role remains unclear.

Ang II functions as a significant hormonal mediator in cardiac hypertrophy that can induce a direct injury on cardiomyocytes. Reactive oxygen species (ROS)-dependent activation of the c-Jun N-terminal kinase (JNK) and p38

Key words: icariin, hypertrophy, apoptosis, reactive oxygen species, mitogen activated protein kinases
pathways has been shown to play a critical role in the effect Ang II exhibits on cardiomyocytes (10). A previous study demonstrated that icariin inhibits the production of ROS and blocks the activity of the JNK and p38 pathways in lipopolysaccharide (LPS)-treated microglial cells (11). However, the effect of icariin on Ang II-induced cardiomyocyte injury and the underlying mechanisms remain unknown. In the present study, a hypertrophic model was used in Ang II-stimulated H9c2 cardiomyocytes. The aims were to determine whether icarin treatment directly prevented cardiomyocytes from hypertrophy and apoptosis and to determine whether the cardioprotective effect of icariin was mediated via the inhibition of the ROS-dependent JNK and p38 pathways.

**Materials and methods**

**Reagents.** Icariin (≥94% purity as determined by high performance liquid chromatography analysis), Ang II and 2,7'-dichlorofluorescein diacetate (DCFH-DA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium: Nutrient mixture F-12 (DMEM/F12), fetal bovine serum (FBS), trypsin, penicillin and streptomycin were purchased from Gibco-BRL (Carlsbad, CA, USA). TRIZol, Alexa Fluor® 488 goat anti-mouse IgG and SlowFade Gold antifade reagent with 4',6-diamidino-2-phenylindole (DAPI) were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). A Transcriptor First Strand cDNA synthesis kit and LightCycler 480 SYBR Green 1 Master Mix were purchased from Roche Diagnostics (Basel, Switzerland). Antibodies against α-actinin and an ApopTag® Plus Fluorescein In Situ Apoptosis detection kit were purchased from Millipore Corporation (Billerica, MA, USA). Primary antibodies were purchased from Cell Signaling Technology, Inc. (Beverley, MA, USA) and IRDye 800CW conjugated secondary antibodies were obtained from LI-COR Biosciences (Lincoln, NE, USA).

**H9c2 cardiomyocyte culture.** The H9c2 embryonic rat heart-derived cell line was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Icariin was dissolved in dimethyl sulfoxide at a concentration of 10 mmol/l for storage. Cells were cultured in DMEM/F12 1:1 medium, supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin, in a humidified incubator with an atmosphere of 5% CO₂ at 37°C. Cells were seeded at a density of 1x10⁶ cells per well into six-well culture plates for mRNA extraction, 5x10⁵ cells per well into six-well culture plates for cell surface area (CSA) and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis, 5x10⁶ cells per well in 96-well plates for ROS detection and 1x10⁷ cells per well into 100 mm culture dishes for protein extraction. The cells were cultured in serum-free DMEM/F12 1:1 medium for 24 h and pretreated with icariin for 1 h prior to stimulation with Ang II.

**Cell viability.** Cell viability was analyzed using the Cell Counting Kit-8 (CCK-8) assay. Following icariin treatment for 48 h, 10 µl CCK-8 solution was added to each well of the 96-well plate and then incubated for an additional 4 h. Absorbance was measured at 450 nm using a microplate reader (Synergy HT; BioTek, Winooski, VT, USA). The percentage of cell viability was calculated according to the following formula: Cell viability (%) = optical density (OD) of the treatment group/OD of the control group x 100%.

**Quantitative polymerase chain reaction (qPCR).** To detect the mRNA expression levels of hypertrophic markers, including atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), qPCR was performed as described previously (12). Total RNA was extracted from cultured H9c2 cells using TRIzol and 2-µg samples of RNA were reverse-transcribed into cDNA using the Transcriptor First Strand cDNA synthesis kit. PCR amplifications were quantified using a LightCycler 480 SYBR Green 1 Master Mix and GAPDH was used as the internal control.

**TUNEL staining.** Apoptotic nuclei were labeled using TUNEL staining with a ApopTag® Plus Fluorescein In Situ Apoptosis Detection kit, according to the manufacturer’s instructions (14). Cells on the coverslips were fixed with 1% paraformaldehyde in PBS, stained with TUNEL reagents and the nuclei were stained with DAPI. The cell apoptotic index was calculated as the percentage of apoptotic nuclei/total number of nuclei.

**ROS detection.** Intracellular ROS generation was determined using DCFH-DA, which becomes fluorescent on oxidation to DCF by H₂O₂ produced within cells. Following Ang II or/and Icariin treatments, H9c2 cells were washed twice and incubated with 5 µM DCFH-DA solution in serum-free medium at 37°C for 30 min in the dark. Data were then collected using a fluorescent reader (Synergy HT; BioTek) at excitation/emission wavelengths of 485/530 nm. A fluorescent microscope was also used to evaluate the DCF fluorescence of the cells on the coverslips.

**Western blotting.** Western blotting was performed as described previously (13). Cells were lysed in radioimmuno-precipitation assay lysis buffer and 50-µg samples of the cell lysates were electrophoresed on 10% SDS-PAGE gels. The proteins were then transferred onto Immobilon™ transfer membranes (Millipore Corporation) and blocked with 5% non-fat milk for 2 h. The membranes were incubated with antibodies specific for phosphorylated (p)-JNK, p-extracellular signal-related kinase (ERK), p-p38, total (T)-JNK, T-ERK, T-p38, Bcl-2, Bax, cleaved-caspase 3 or GAPDH overnight at 4°C. The samples were then incubated with IRDye 800CW conjugated secondary antibodies and the blots were scanned.
by a two-color infrared imaging system (Odyssey, LI-COR Biosciences).

Statistical analysis. Data are presented as the mean ± SEM and analyzed using a statistical software (SPSS 16.0; SPSS Inc., Chicago, IL, USA). Differences among the groups were determined by two-way analysis of variance followed by Tukey's post hoc test. A comparison between the control and all the treatment groups was performed using the unpaired Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of icariin on cell viability. The potential cytotoxicity of icariin was analyzed using a CCK-8 assay. H9c2 cells were incubated with various concentrations of icariin (0.1, 1, 5 or 10 µM) for 48 h. Cell viability in icariin-treated cells exhibited no significant differences when compared with the control cells, indicating that icariin at a concentration of 0.1, 1, 5 or 10 µM did not possess any cytotoxicity in H9c2 cells (Fig. 1).

Effect of icariin on ANP and BNP induction. The effect of icariin at various concentrations (0.1, 1, 5 or 10 µM) on the induction of ANP and BNP in response to Ang II was determined. Stimulation with Ang II for 24 h markedly increased the mRNA expression levels of ANP and BNP in H9c2 cells and icariin treatment markedly attenuated this increase in a concentration-dependent manner (Fig. 2A). Icariin at a concentration of 10 µM significantly blocked the induction of ANP and BNP in response to Ang II at various time points, thus, this concentration was selected for further investigations (Fig. 2B).

Icariin attenuates the Ang II-induced increase in CSA. CSAs of H9c2 cells were determined by α-actinin staining to further evaluate the antihypertrophic effect of icariin. Ang II stimulation for 48 h resulted in a significant increase in the CSAs of H9c2 cells. However, icariin treatment markedly attenuated
Figure 3. Effect of icariin on CSA. (A) Representative images and (B) quantitative results demonstrating that 10 µM icariin inhibited Ang II (1 µM; 48 h)-induced enlargement of H9c2 cells. *P<0.05, vs. control; #P<0.05, vs. Ang II-treated cells. CSA, cell surface area; Ang II, angiotensin II.

Figure 4. Effect of icariin on apoptosis. (A) Representative images and (B) quantitative results demonstrating that 10 µM icariin attenuated cell apoptosis following stimulation with Ang II for 48 h, as shown by TUNEL staining. (C) Representative blots and (D) quantitative results demonstrating that 10 µM icariin decreased the protein expression levels of Bax and cleaved-caspase 3, but increases the expression levels of Bcl-2 in response to Ang II stimulation. *P<0.05, vs. control; †P<0.05, vs. Ang II-treated cells. Ang II, angiotensin II; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling.
the increase, indicating that Ang II-induced enlargement of H9c2 cells was suppressed by icariin (Fig. 3).

Icariin inhibits Ang II-induced apoptosis. To investigate the role of icariin in Ang II-induced apoptosis of H9c2 cells, TUNEL staining was used to identify the apoptotic nuclei. A marked increase in the number of TUNEL-positive nuclei was observed in cells that had been incubated with Ang II, and icariin treatment markedly reduced Ang II-induced cell apoptosis (Fig. 4A and B). In addition, icariin decreased the protein expression levels of Bax and cleaved-caspase 3 in H9c2 cells in response to Ang II (Fig. 4C and D), which may mediate the antiapoptotic effect of icariin. Furthermore, the decreased level of antiapoptotic protein Bcl-2 in Ang II-treated H9c2 cells was restored with icariin treatment (Fig. 4C and D).

Icariin decreases the production of ROS. Fluorescence intensity in cells following incubation with DCFH-DA, exhibited by a fluorescent reader, revealed that Ang II increased the ROS content in a time-dependent manner. In addition, icariin treatment markedly blocked Ang II-induced ROS production at the indicated time points (Fig. 5A). DCF-derived fluorescence observed with a microscope also demonstrated that icariin inhibited the accumulation of intracellular ROS in Ang II-treated cells, which was in accordance with the results of the fluorescent reader (Fig. 5B).

Icariin blocks the activation of JNK and p38 pathways in response to Ang II. To further explore the mechanisms underlying the antihypertrophic and antiapoptotic effects of icariin in Ang II-treated H9c2 cells, western blotting was used.
to detect the phosphorylation levels of JNK and p38, which are key mediators of cardiac hypertrophy and apoptosis. Phosphorylated levels of JNK and p38 were shown to be markedly elevated by Ang II. However, icariin treatment inhibited the phosphorylation of JNK and p38 in response to Ang II at the indicated time points (Fig. 6).

Discussion

Icariin, the major active component isolated from plants of the Epimedium family, has been reported to exhibit potential protective effects on the cardiovascular system (8,9). However, it is not known whether icariin has a direct effect on Ang II-induced cardiomyocyte injury. In the present study, icariin was found to protect H9c2 cells from hypertrophy and apoptosis in response to Ang II. The beneficial effect of icariin may be mediated by inhibiting the ROS-dependent JNK and p38 pathways.

Enlargement and apoptotic loss of cardiomyocytes play critical roles in the transition from cardiac hypertrophy to heart failure (5). H9c2 cells, an embryonic rat-heart-derived cell line, maintain similar characteristics to primary cardiomyocytes, including morphology, protein expression, electrophysiological properties and hypertrophic responses (15,16). Ang II functions as a significant hormonal mediator in cardiac hypertrophy, which can induce pathological growth and apoptosis in cardiomyocytes (17). In the current study, an Ang II-induced injury model in H9c2 cells was used to evaluate the direct protection of icariin on cardiomyocytes. A previous study demonstrated that icariin attenuated cardiac remodeling in rats with congestive heart failure by inhibiting MMP activity and cardiomyocyte apoptosis (8), indicating the protective role of icariin in the cardiovascular system. However, whether icariin can provide a direct benefit on cardiomyocytes and the underlying mechanisms remain unclear. The results of the present study revealed that icariin directly repressed Ang II-induced H9c2 cell enlargement and the expression of ANP and BNP, which are considered to be molecular markers of cardiomyocyte hypertrophy. Furthermore, icariin blocked apoptosis in Ang II-treated H9c2 cells by regulating the protein expression of the proapoptotic proteins, Bax and cleaved-caspase 3, as well as the antiapoptotic protein, Bel-2.

Clinical and experimental studies have provided substantial evidence that ROS production, reflecting the status of oxidative stress, is enhanced in hypertrophic and failing hearts (18,19). Ang II, norepinephrine and mechanical stretch can induce the production of ROS associated with the hypertrophic response in cardiomyocytes (20-22). Increased intracellular ROS levels in a hypertrophic heart contribute to the progression of cardiac remodeling and heart failure. H2O2, a major source of ROS, directly induces cardiomyocyte hypertrophy and apoptosis in vitro (23,24). Therefore, antioxidants that block ROS production exhibit therapeutic potential in treating cardiac hypertrophy. Previous studies have shown that icariin attenuated H2O2-induced neurotoxicity (25) and inhibited ROS production in LPS-treated microglia (11), demonstrating the antioxidative effect of icariin. In the present study, icariin was shown to block the production of ROS in H9c2 cells, which may mediate the cardioprotective effect of icariin.

Increased ROS levels not only lead to the oxidation and damage of macromolecules, membranes and DNA, but also function as a secondary messengers in cellular signaling (26). Activation of JNK and p38, members of the mitogen-activated protein kinase family, has been reported to be induced by ROS (27). Following activation, JNK and p38 phosphorylate a wide array of intracellular targets, including numerous transcription factors, resulting in the reprogramming of cardiac gene expression, the hypertrophic phenotype and apoptosis of cardiomyocytes (28). Inhibition of the JNK or p38 pathways in cardiomyocytes results in attenuated hypertrophic growth induced by agonist stimulation (29). Previous evidence revealed that Ang II-induced activation of JNK and p38 in cardiomyocytes is ROS-dependent (10), indicating that treatment targeting the production of ROS may suppress the JNK and p38 pathways and subsequently result in a protective effect on Ang II-induced injury in cardiomyocytes. The results of the present study demonstrated that icariin downregulated ROS levels and the phosphorylation of JNK and p38 in Ang II-treated H9c2 cells. These observations indicate that icariin protects H9c2 cells from Ang II-induced hypertrophy and apoptosis via the inhibition of the ROS-dependent JNK and p38 pathways.

In conclusion, the current study has demonstrated a previously unknown effect of icariin on Ang II-induced cardiomyocyte hypertrophy and apoptosis through inhibiting the ROS-dependent JNK and p38 pathways. The results of the present study provide experimental evidence for the application of icariin in the treatment of cardiac hypertrophy.

Acknowledgements

The study was supported by grants from the National Natural Science Foundation of China (nos. 81300070 and 81270303) and the Fundamental Research Funds for the Central Universities of China (no. 2012302020212).

References

1. Bui AL, Horwich TB and Fonarow GC: Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8: 30–41, 2011.
2. Shah AM and Mann DL: In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 378: 704-712, 2011.
3. Rohini A, Agrawal N, Koyani CN and Singh R: Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61: 269-280, 2010.
4. van Berlo JH, Mailett M and Molkentin JD: Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 123: 37-45, 2013.
5. Mann DL, Barger PM and Burkhoff D: Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 60: 2465-2472, 2012.
6. Xu CQ, Liu BJ, Wu JF, et al: Icariin attenuates LPS-induced acute inflammatory responses: involvement of PI3K/Akt and NF-kappaB signaling pathway. Eur J Pharmacol 642: 146-153, 2010.
7. Li WW, Gao XM, Wang XM, Guo H and Zhang BL: Icariin inhibits hydrogen peroxide-induced toxicity through inhibition of phosphorylation of JNK/p38 MAPK and p53 activity. Mutat Res 708: 1-10, 2011.
8. Song YH, Cai H, Gu N, Qian CF, Cao SP and Zhao ZM: Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. J Pharm Pharmacol 63: 541-549, 2011.
9. Chung BH, Kim JD, Kim CK, et al: Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun 376: 404-408, 2008.
10. Nishida M, Tanabe S, Maruyama Y, et al: G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 280: 18434-18441, 2005.

11. Zeng KW, Fu H, Liu GX and Wang XM: Icariin attenuates lipopoly saccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways. Int Immunopharmacol 10: 668-678, 2010.

12. Zhou H, Bian ZY, Zong J, et al: Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension 60: 802-809, 2012.

13. Zhou H, Shen DF, Bian ZY, et al: Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload. PLoS One 6: e26744, 2011.

14. Zhou H, Yang HX, Yuan Y, et al: Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFbeta/Smad5 and NF-xB pathways. Mol Histol 44: 357-367, 2013.

15. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W and Schultz G: Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69: 1476-1486, 1991.

16. Watkins SJ, Borthwick GM and Arthur HM: The H9c2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47: 125-131, 2011.

17. Fortuño MA, Ravassa S, Fortuño A, Zalba G and Díez J: Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 38: 1406-1412, 2001.

18. Tsutsui H, Kinugawa S and Matushima S: Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 301: H2181-H2190, 2011.

19. Anilkumar N, Sirker A and Shah AM: Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci (Landmark Ed) 14: 3168-3187, 2009.

20. Brasier AR, Jamaluddin M, Han Y, Patterson C and Runge MS: Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212: 155-169, 2000.

21. Amin JK, Xiao L, Pimental DR, et al: Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33: 131-139, 2001.

22. Pimentel DR, Amin JK, Xiao L, et al: Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89: 453-460, 2001.

23. Essick EE, Ouchi N, Wilson RM, et al: Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 301: H984-H993, 2011.

24. Long X, Goldenthal MJ, Wu GM and Marín-García J: Mitochondrial Ca2+ flux and respiratory enzyme activity decline are early events in cardiomyocyte response to H2O2. J Mol Cell Cardiol 37: 63-70, 2004.

25. Zhang L, Huang S, Chen Y, Wang Z, Li E and Xu Y: Icariin inhibits hydrogen peroxide-mediated cytotoxicity by up-regulating sirtuin type I-dependent catalase and peroxiredoxin. Basic Clin Pharmacol Toxicol 107: 899-905, 2010.

26. Maulik SK and Kumar S: Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods 22: 359-366, 2012.

27. Han MJ, Kim BY, Yoon SO and Chung AS: Cell proliferation induced by reactive oxygen species is mediated via mitogen-activated protein kinase in Chinese hamster lung fibroblast (V79) cells. Mol Cells 15: 94-101, 2003.

28. Balakumar P and Jagadeesh G: Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res 62: 365-383, 2010.

29. Liang Q and Molkentin JD: Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35: 1385-1394, 2003.